Boston Scientific Receives FDA Approval For Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System

Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable polymer drug-eluting stent (DES).
Source: Medical Design Online News - Category: Medical Equipment Source Type: news